Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex, class II, DQ alpha 1 (HLA-DQA1) is a gene encoding the alpha chain of an MHC class II molecule that forms a heterodimer with the DQ beta 1 chain (HLA-DQB1)[2]. This membrane protein complex is present on the surface of antigen-presenting cells such as dendritic cells, macrophages, and B cells; it binds to peptides derived from extracellular proteins, presenting them to CD4+ T lymphocytes and initiating adaptive immune responses[2][1]. The HLA-DQA1 gene is highly polymorphic, allowing for diverse peptide binding and influencing susceptibility to autoimmune diseases and transplant compatibility[2][3]. HLA-DQ molecules are not direct drug targets, but their role is critical in immunological diseases and as a biomarker in diagnostic testing[2].
Not directly drug-targeted; drugs that modulate T cell activation or general immune function may indirectly affect this pathway
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major histocompatibility complex, class II, DQ alpha 1 (HLA-DQ alpha 1 (commonly HLA-DQA1)).